BIT Stock Overview
A biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Biotron Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.019 |
| 52 Week High | AU$0.13 |
| 52 Week Low | AU$0.016 |
| Beta | -0.61 |
| 11 Month Change | 0% |
| 3 Month Change | -36.67% |
| 1 Year Change | -82.73% |
| 33 Year Change | -61.22% |
| 5 Year Change | -72.46% |
| Change since IPO | -77.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIT | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -9.5% | -3.7% | -1.1% |
| 1Y | -82.7% | 19.0% | 16.1% |
Return vs Industry: BIT underperformed the Australian Biotechs industry which returned 19% over the past year.
Return vs Market: BIT underperformed the Australian Market which returned 16.1% over the past year.
Price Volatility
| BIT volatility | |
|---|---|
| BIT Average Weekly Movement | 15.0% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: BIT's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: BIT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Michelle Miller | www.biotron.com.au |
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is based in Sydney, Australia.
Biotron Limited Fundamentals Summary
| BIT fundamental statistics | |
|---|---|
| Market cap | AU$17.14m |
| Earnings (TTM) | -AU$3.44m |
| Revenue (TTM) | AU$1.65m |
10.4x
P/S Ratio-5.0x
P/E RatioIs BIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIT income statement (TTM) | |
|---|---|
| Revenue | AU$1.65m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.65m |
| Other Expenses | AU$5.08m |
| Earnings | -AU$3.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0038 |
| Gross Margin | 100.00% |
| Net Profit Margin | -208.89% |
| Debt/Equity Ratio | 0% |
How did BIT perform over the long term?
See historical performance and comparison